{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:20:57Z","timestamp":1782080457831,"version":"3.54.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Childhood cancers, with leukemia at the forefront, comprise 97% acute leukemia and 3% chronic leukemia, with 75% of acute leukemias being of lymphoblastic origin. Over the past 50 years, survival rates have witnessed a remarkable increase, progressing from around 10% to achieving cure rates exceeding 90% in certain childhood ALL subgroups with the advent of combined therapies. Between 1999 and 2018, a total of 123 patients diagnosed with B-ALL were initially identified, but after applying exclusion criteria, 105 patients were included in the evaluation, who were treated with COG protocols at our center. The mean follow-up duration for patients was determined to be a median of 74 months (min to max: 2 to 228 months). When the cases were evaluated at the end of the study, 59 of 59 individuals in the standard risk group (100%), 21 of 26 individuals in the high-risk group (80.7%), and 14 of 20 individuals in the very high group (70%) were alive. Patients were categorized into 4 groups based on the methotrexate (MTX) doses they received during Phase 3 and Phase 5 of treatment. Event-free survival and overall survival were evaluated among these groups. It was observed that patients in the standard-risk group had significantly higher event-free and overall survival rates. However, no significant difference was found in survival rates when evaluated based on the treatment groups each risk group received by the patients.<\/jats:p>","DOI":"10.1097\/mph.0000000000002995","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T20:07:13Z","timestamp":1736539633000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Capizzi and High-dose Methotrexate Approaches in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0958-7824","authenticated-orcid":false,"given":"Ezgi","family":"Yalcin Gungoren","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Istanbul University, Cerrahpasa Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basak","family":"Koc","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Istanbul University Oncology Institute, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Zulfikar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Istanbul University Oncology Institute, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdn182","article-title":"Biologic features and treatment outcome of secondary acute lymphoblastic leukemia\u2014a review of 101 cases","volume":"19","author":"Shivakumar","year":"2008","journal-title":"Ann Oncol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.leukres.2014.03.016","article-title":"A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol","volume":"38","author":"Koka","year":"2014","journal-title":"Leuk Res"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clml.2020.08.025","article-title":"Acute complications and survival analysis of childhood acute lymphoblastic leukemia: a 15-year experience","volume":"21","author":"Ozturk","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","article-title":"Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R13-20250527","first-page":"460","article-title":"[Acute lymphoblastic leukemia: pathophysiology and current therapy]","volume":"58","author":"Imai","year":"2017","journal-title":"Rinsho Ketsueki"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/08880018.2011.629859","article-title":"ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia\u2014experience of a single center","volume":"29","author":"Kocak","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00277-014-2106-0","article-title":"The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol","volume":"93","author":"Gunes","year":"2014","journal-title":"Ann Hematol"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1097\/MPH.0000000000000751","article-title":"Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster\/Hong Kong Acute Lymphoblastic Leukemia (BFM95\/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study","volume":"39","author":"Dujua","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ajh.25124","article-title":"Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China","volume":"93","author":"Cui","year":"2018","journal-title":"Am J Hematol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mpo.1156","article-title":"Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors","volume":"37","author":"Ishii","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/MPH.0000000000000653","article-title":"The impact of socioeconomic factors on the outcome of childhood acute lymphoblastic leukemia (ALL) treatment in a low\/middle income country (LMIC)","volume":"38","author":"Jabeen","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/MPH.0b013e3181ed163c","article-title":"Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience","volume":"32","author":"Hazar","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.mph.0000132735.93396.92","article-title":"Outcome and prognostic factors of acute lymphoblastic leukemia in children at the National Cancer Institute, Egypt","volume":"26","author":"Hussein","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"issue":"Pt B","key":"R26-20250527","doi-asserted-by":"crossref","first-page":"101733","DOI":"10.1016\/j.canep.2020.101733","article-title":"Childhood cancer: survival, treatment modalities, late effects and improvements over time","volume":"71","author":"Erdmann","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41375-020-01024-0","article-title":"Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015","volume":"35","author":"Reedijk","year":"2021","journal-title":"Leukemia"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12185-018-2440-4","article-title":"Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children\u2019s Cancer Study Group (TCCSG) Study L04-16","volume":"108","author":"Takahashi","year":"2018","journal-title":"Int J Hematol"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MPH.0b013e318271f43f","article-title":"Outcome of modified St Jude total therapy 13A for childhood acute lymphoblastic leukemia in the southeast region of Turkey","volume":"35","author":"Koc","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2009.250","article-title":"Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia","volume":"24","author":"Conter","year":"2010","journal-title":"Leukemia"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"Moricke","year":"2010","journal-title":"Leukemia"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/leu.2009.249","article-title":"Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97","volume":"24","author":"Escherich","year":"2010","journal-title":"Leukemia"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":"Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002","volume":"32","author":"Stary","year":"2014","journal-title":"J Clin Oncol"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"R36-20250527","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Gokbuget","year":"2024","journal-title":"Blood"},{"key":"R38-20250527","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T20:03:10Z","timestamp":1748376190000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002995","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"2024-07-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}